Tirzepatide benefits and uses

What the evidence covers

Most findings come from randomized phase 3 trials of a once-weekly injection, some with thousands of adults.⁷⁸ A few come from a phase 2 trial, from mice or from cell studies, which are earlier-stage evidence.⁹¹⁰¹¹ Several findings led to approved uses, while others, such as the liver results, still need larger and longer trials.¹² SURMOUNT-1, the main weight trial, was supported by Eli Lilly, the maker.¹³

Approved uses

• Blood sugar in type 2 diabetes (Mounjaro): approved with diet and exercise for adults and children 10 and older.¹⁴
• Heart risk in type 2 diabetes (Mounjaro): approved in August 2026 to cut the chance of a major cardiovascular event (cardiovascular death, non-fatal heart attack or non-fatal stroke) in high-risk adults.¹⁵¹⁶
• Weight (Zepbound): approved for long-term weight reduction and maintenance in adults with obesity, or with overweight plus a weight-related condition.¹⁷
• Obstructive sleep apnea (Zepbound): approved in December 2024 for moderate to severe sleep apnea in adults with obesity.¹⁸ FDA called it the first drug treatment option for certain patients with the condition.¹⁹
• European Union: Mounjaro is authorised for type 2 diabetes in adults and in children aged 10 and older, and for weight management in adults.²⁰²¹

Reported benefits by evidence level

• Blood sugar (phase 3, 478 and 1,879 adults): HbA1c fell about 1.9 to 2.3 percentage points over 40 weeks, more than with semaglutide 1 mg in the head-to-head trial.¹²² Detail: Tirzepatide and blood sugar.
• Children and teens with type 2 diabetes (randomized trial, 99 patients aged 10 and older): both doses tested, 5 mg and 10 mg weekly, beat placebo on HbA1c over 30 weeks.²³²⁴
• Weight in type 2 diabetes (phase 3, 478 adults): body weight dropped by 7.0 to 9.5 kg over 40 weeks.²⁵ The trial recorded no clinically significant or severe hypoglycemia on tirzepatide.²⁶
• Insulin sensitivity (label, clamp study): 28 weeks of treatment made the body respond better to insulin in people with type 2 diabetes.²⁷
• Body weight (phase 3, 2,539 adults): weight dropped by an average of 15.0% to 20.9% over 72 weeks, against 3.1% with placebo.²³ On 10 mg and 15 mg, half or more of participants (50% and 57%) lost at least a fifth of their weight.²⁸ Detail: Tirzepatide and weight loss.
• Diabetes prevention (phase 3, 1,032 adults with prediabetes): over 176 weeks, new type 2 diabetes was diagnosed in 1.3% of the tirzepatide groups and 13.3% of the placebo group.²⁹⁴
• Sleep apnea (phase 3, two trials, 469 adults): breathing interruptions fell by 25.3 and 29.3 events per hour, versus 5.3 and 5.5 on placebo.³⁰⁵³¹
• Waist size (phase 3b, 751 adults): waists shrank by 18.4 cm on tirzepatide and 13.0 cm on semaglutide over 72 weeks.³²³³
• Heart and metabolic markers (phase 3, 2,539 adults): all prespecified cardiometabolic measures improved.³⁴
• Heart events in type 2 diabetes (phase 3, 13,299 adults): 12.2% of the tirzepatide group and 13.1% of the dulaglutide group had a major cardiovascular event.³⁵ The result met the noninferiority goal but did not show superiority.³⁵
• Heart failure (randomized trial, 731 adults): in heart failure with preserved ejection fraction and obesity, cardiovascular death or worsening heart failure occurred in 9.9%, versus 15.3% on placebo.³⁶³⁷
• Liver (phase 2, 190 adults): fatty liver disease with inflammation (MASH) resolved without worse scarring in 44% to 62%, versus 10% on placebo.³⁸⁹³⁹ The authors called for larger, longer trials.¹²
• Keeping weight off (phase 3, 670 adults): after 36 weeks on tirzepatide, continuing for another 52 weeks brought a further 5.5% loss, whereas switching to placebo led to a 14.0% weight gain.⁴⁰⁴¹
• A lower maintenance dose (phase 3b, 378 adults randomized): after 60 weeks at the full dose, stepping down to 5 mg kept modeled weight 16.6% below baseline at week 112, versus 9.9% on placebo.⁴²⁴³

Neither the heart failure result nor the liver result is among the approved uses in the current labels.^14151744

What the evidence does not show

• Muscle gain: not shown. According to the Zepbound label, the weight lost is more fat than lean mass, which means some lean mass goes too.⁴⁵
• Skin or hair benefits: none reported. Hair loss is a listed side effect, at 4% to 5% versus 1% on placebo.⁴⁶
• Other sleep problems: the sleep trials enrolled adults with obstructive sleep apnea.³⁰ We found no trial of tirzepatide for insomnia.
• A lasting effect after stopping: the SURMOUNT-4 authors found that stopping treatment led to substantial weight regain.⁴⁷

Limits to keep in mind

• Side effects: stomach and bowel effects were common, mostly during dose increases.³⁴ See Tirzepatide side effects.
• Study conditions: the results come from controlled trials in which weekly doses were raised on a set schedule, mostly over 40 to 72 weeks.⁴⁸⁷ Label schedules and the prescriber's role are on Tirzepatide dosage.
• Research-labeled vials: FDA calls research-labeled GLP-1 products sold to consumers of unknown quality, so trial benefits say nothing reliable about such vials.⁶ Lab handling is covered in How to reconstitute Tirzepatide.

Back to the Tirzepatide profile.